Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Next generation Sepsis pathogen diagnostics: Revolutionary device for rapid detection of Sepsis

Project description

Rapid diagnosis to save lives of sepsis patients

Sepsis is a life-threatening medical emergency that kills more than 11 million people each year. An extreme response to an infection, 80 % of deaths from sepsis could have been prevented with faster diagnosis and treatment. However, present tests are time-consuming laboratory procedures. The EU funded SepTec project is developing a revolutionary, rapid solution in the form of a diagnostic device that screens blood in vitro to detect and identify dangerous pathogens within 15 minutes at extremely low concentrations. It will facilitate accurate diagnosis and treatment of sepsis infection up to 4 days earlier than is currently possible, reducing mortality by 50 %.

Objective

49M patients are diagnosed with Sepsis and 11M die annually worldwide and costs over €30 billion to treat. This is a senseless tragedy as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.
SepTec is the groundbreaking, cost-effective technology required to provide the solution.
SepTec is a patent-pending in-vitro diagnostic device that screens blood for the diagnosis of sepsis infection, detecting and identifying pathogens within 15 minutes at very low concentrations (<10 CFU/ml) without the need complicated lab tests. Preliminary health economics research shows that our rapid Sepsis infection diagnosis will result in patients receiving the correct treatment between 2 and 4.5 days earlier than in current protocols (resulting in a consequent 50% reduction in mortality rate), 25 times fewer patients receiving unnecessary antibiotics and a healthcare saving between €17-40m per 5m population.
The global point of care market is expected to be valued €50.51bn by year 2026, (CAGR of 9.6%). Within this market, the market for point-of-care tests (POCT) for infectious diseases (including sepsis) is €3.7bn annually and sepsis specific POC diagnostics testing market is expected to grow from €1bn by 2026. To exploit this lucrative market opportunity, we must complete an innovation project to progress our highly promising results into a product suitable for a large-scale clinical validation, mass manufacturing and subsequently commercialization.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Coordinator

NOVUS DIAGNOSTICS LIMITED
Net EU contribution
€ 2 418 675,00
Address
NATIONAL INSTITUTE FOR CELLULAR BIOTECHNOLOGY DCU GLASNEVIN CAMPUS, BALLYMUN ROAD
D09 NR58 Dublin
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 455 250,00
My booklet 0 0